The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
Articles
Facing the challenges of bringing medtech to Germany
January 29, 2021
Key contacts
Additional contributors
-
Oriol Viader Llargués
Consulting Associate
-
Lukas Ziegler
Associate
Upcoming events
Swiss Biotech Day 2026
CRA is a proud sponsor of the premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful...
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...